Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × elacestrant × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Carboplatin 26 pembrolizumab 23 Cisplatin 22 Nivolumab 19 Paclitaxel 19 Gemcitabine 16 Ipilimumab 14 Pemetrexed 13 Rituximab 13 Cyclophosphamide 12 Dexamethasone 11 Lenalidomide 9 daratumumab 9 Fluorouracil 8 durvalumab 8 trastuzumab deruxtecan 8 Docetaxel 7 Leucovorin 7 Prednisone 7 Bortezomib 6 Capecitabine 6 Doxorubicin 6 Oxaliplatin 6 atezolizumab 6 osimertinib 6 Bevacizumab 5 Cytarabine 5 Etoposide 5 Sunitinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡